The Johns Hopkins University

Assoicated Universties, Inc.

Duke University

Brookhaven Science Associates, Lcc

Other

Northwestern University

Research Corporation Technologies, Inc.

Ronnie Charles Mease

Martin Gilbert Pomper

Sangeeta Ray

Ying Chen

Suresh C Srivastava

Xing Yang

Leonard F Mausner

Catherine Anne Foss

Hassan Shallal

Samuel Ray Denmeade

Michael R Zalutsky

Il Minn

Robert Francis Dannals

Hayden T Ravert

Ganesan Vaidyanathan

Hong Fan

Sachin S Chandran

Ray Sangeeta

Mark P Sweet

Jean-Francois Gestin

Daniel P Holt

Vivek Kumar

Thomas J Meade

Steven M Rowe

John G McAfee

Haofan Wang

Matthew W Rotz

Mohamad Allaf

Steven D Leach

Michael Gorin

Kathryn L Kolsky

Carol Lambert

Matthew Rotz

Robert F Dannals

Steven Rowe

Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off-target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.

PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy

Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.

PSMA-binding agents and uses thereof

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.

PSMA targeted fluorescent agents for image guided surgery

Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.

Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy

Methods, and related compositions, for the improved synthesis of [F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [F]DCFPyL so produced.

Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [F]DCFPYL

Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.

PSMA-targeting compounds and uses thereof

Triazole conjugated urea-based and thiourea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used to image cells and tumors that express PSMA. Methods of synthesizing radiofluorinated triazole conjugated urea-based and thiourea-based scaffolds also are disclosed.

Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof

Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [F]DCFPyL

Highly potent and selective radionuclide-based imaging and therapy agents targeting carbonic anhydrase IX with minimum non-specific organ uptake are disclosed. Methods of imaging and/or treating carbonic anhydrase IX-expressing cells or tumors also are disclosed.

Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX and uses thereof

PSMA-targeted PET/SPECT agents for imaging PSMA-positive cancer and or tumor neovasculature and PSMA-targeted radiotherapeutic agent for the treatment of PSMA-positive cancer or tumor neovasculature are disclosed. Methods of imaging PSMA expressing tumors, or cells and kits also are disclosed.

68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents

Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.

Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy

Growing community of inventors

Fairfax Station, VA, United States of America

Ronnie Charles Mease